Colon Cancer Staging and Treatment
Colon cancer is staged using the TNM system (T=tumor depth, N=lymph node involvement, M=metastases), with pathologic staging being the gold standard after surgical resection, and treatment decisions are primarily driven by stage: surgery alone for stages I-II, surgery plus adjuvant chemotherapy for stage III, and chemotherapy with or without surgery for stage IV disease. 1
Staging System
Pathologic staging should be performed according to the TNM system with the following key components 1, 2:
- T stage: Depth of tumor invasion through bowel wall (T1-T4)
- N stage: Regional lymph node involvement (N0-N2)
- M stage: Presence of distant metastases (M0-M1)
Preoperative Staging Workup
The essential preoperative staging includes 1:
- Clinical examination
- Complete blood counts, liver and renal function tests
- Carcinoembryonic antigen (CEA) level
- Chest imaging (X-ray or CT scan)
- CT scan of abdomen
- Complete colonoscopy (or postoperative if obstructed)
Important caveat: CT staging has significant limitations for early colon cancer—in a nationwide study, CT correctly staged only 40% of cT1-2 tumors, with 50% actually being pT3 and 9% being pT4 3. Therefore, CT should not be the sole basis for treatment decisions in suspected early-stage disease.
Treatment by Stage
Stage I (T1-2, N0, M0)
Surgery alone is curative—no adjuvant chemotherapy indicated 1, 2.
- Perform en bloc resection following standard oncologic principles
- Ensure adequate lymph node harvest (≥12 nodes examined)
- Surveillance only postoperatively
Stage II (T3-4, N0, M0)
Surgery is the primary treatment; adjuvant chemotherapy may be considered only in high-risk patients 1.
High-risk features that warrant consideration of adjuvant chemotherapy include 1:
- T4 tumors
- Poorly differentiated or undifferentiated histology
- Lymphovascular invasion
- Perineural invasion
- Bowel obstruction or perforation at presentation
- <12 lymph nodes examined
- Elevated CEA level
For average-risk stage II patients without these features, adjuvant chemotherapy benefit remains unproven 4. Additionally, patients with high microsatellite instability (MSI-H) have excellent prognosis and show limited benefit from 5-FU-based chemotherapy 4.
Stage III (Any T, N1-2, M0)
Adjuvant chemotherapy is definitively recommended for all stage III patients 1, 5.
Standard adjuvant regimens 1, 6:
First-line options:
- FOLFOX (5-FU/leucovorin plus oxaliplatin): Significantly improves disease-free survival and overall survival compared to 5-FU/LV alone
- CapeOx (capecitabine plus oxaliplatin): Equivalent efficacy to FOLFOX
Alternative options:
- 5-FU/leucovorin regimens (infusional or bolus)
- Capecitabine monotherapy: At least as effective as and less toxic than bolus 5-FU/LV
Duration of therapy 5:
Based on the IDEA collaboration (>12,000 patients), treatment duration should be risk-stratified:
- Low-risk stage III (T1-3, N1): 3 months of CapeOx is non-inferior to 6 months, with significantly lower neurotoxicity (3% vs 9% grade ≥3)
- High-risk stage III (T4 or N2): 6 months of oxaliplatin-based therapy remains standard
This represents a major paradigm shift allowing toxicity reduction in appropriate patients.
Stage IV (Any T, Any N, M1)
Treatment depends on resectability of metastases 7, 8:
Resectable metastases (liver or lung):
- Surgical resection of both primary and metastases when feasible
- Primary tumor resection combined with chemotherapy provides the best long-term survival compared to chemotherapy alone or surgery alone 8
- Follow with adjuvant chemotherapy
Unresectable metastases:
- Palliative chemotherapy is recommended 7
- 5-FU/leucovorin combinations are superior to 5-FU alone
- Addition of oxaliplatin or irinotecan to 5-FU/FA increases response rates and progression-free survival 7
- For BRAF-mutant metastases, targeted therapy options are available 5
Critical point: Even in stage IV disease, primary tumor resection combined with postoperative chemotherapy shows superior survival compared to other treatment strategies when metastases are unresectable 8.
Post-Treatment Surveillance
No single preferred surveillance schedule exists, but the following framework is recommended 1, 2:
- History and physical examination: Every 3 months for 2 years, then every 6 months to complete 5 years
- CEA monitoring: Every 3-6 months for 3 years, then every 6-12 months for years 4-5 (only if initially elevated and patient is candidate for salvage surgery)
- Colonoscopy: At 1 year, then every 3-5 years if negative for polyps
- Liver imaging (ultrasound): Every 6 months for 3 years, then at years 4 and 5
- CT chest/abdomen: Consider for 3 years in high-risk patients
Common Pitfalls to Avoid
Over-reliance on CT for T-staging in early disease: CT has only 40% accuracy for cT1-2 staging 3
Inadequate lymph node harvest: Examination of <12 lymph nodes is itself a high-risk feature and may lead to understaging 1
Routine adjuvant chemotherapy for all stage II patients: Only high-risk stage II patients benefit; MSI-H patients may not benefit from 5-FU therapy 4
Excessive treatment duration in low-risk stage III: 3 months of CapeOx is sufficient for T1-3, N1 disease, avoiding unnecessary neurotoxicity 5
Avoiding surgery in stage IV disease: When feasible, primary tumor resection plus chemotherapy provides superior outcomes even with unresectable metastases 8